WELL Health Technologies and its investee company HEALWELL AI have launched a new artificial intelligence (AI)-powered co-pilot to improve the detection of cardiovascular disease (CVD).
Powered by HEALWELL AI, the co-pilot will assist cardiologists in better identifying patients at high risk of CVD.
WELL Health Technologies is a digital health company focused on tech-enabling healthcare providers. On the other hand, HEALWELL AI is a healthcare technology firm focused on AI and data science for preventative care.
The initiative follows the successful development of WELL AI Decision Support (WAIDS), WELL Health Technologies’ second-generation AI-powered physician co-pilot, also created in collaboration with HEALWELL AI.
The expansion enhances WELL Health Technologies’ existing capabilities in detecting rare and chronic diseases, extending the offerings of WAIDS.
The AI-powered co-pilot for cardiologists will be implemented across WELL Diagnostics Centres in Canada. The tool will be accessible to cardiologists within the WELL Diagnostic Centres network, offering crucial assistance in early detection and effective management of cardiovascular disease.
HEALWELL CEO Alexander Dobranowski said: “The launch of our AI-powered co-pilot for specialists marks a significant milestone in our mission to enhance healthcare through advanced technology.
“By expanding our AI capabilities to include cardiovascular disease detection, we are equipping cardiologists with enhanced tools and decision support necessary to identify at-risk patients earlier, ultimately improving patient outcomes and reducing healthcare costs.
“The integration of this tool into WELL’s Diagnostic Centres is particularly important, as it provides us access to Canada’s largest cardiology group.”
WELL Diagnostics Centres specialises in cardiology and medical diagnostics and has a presence in over 40 locations in Ontario.
WELL Diagnostic Centres CEO Dina Sergi said: “The integration of HEALWELL’s AI-powered co-pilot for cardiologists into our WELL Diagnostic Centres represents a game-changing advancement.
“By offering precise risk stratification and actionable insights, this tool enhances their ability to proactively manage cardiovascular health and improve patient care.”
HEALWELL AI plans to use the technology to expedite advancements in life sciences research and development focused on cardiovascular disease.
Additionally, the healthcare technology firm aims to generate new business prospects for BioPharma Services, its recently acquired clinical research organisation (CRO).
Recently, WELL Health Technologies and its consortium partners received approval for a C$44m ($32m) project to advance AI and interoperability in the healthcare system of Canada.
